<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>Research and Innovation Services</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EB0D755C-E68A-4C5E-BE4D-E35F7F4833CC"><gtr:id>EB0D755C-E68A-4C5E-BE4D-E35F7F4833CC</gtr:id><gtr:firstName>Chim</gtr:firstName><gtr:otherNames>Choy</gtr:otherNames><gtr:surname>Lang</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F6616A73-C8B7-4809-8F4B-36D177DCCF33"><gtr:id>F6616A73-C8B7-4809-8F4B-36D177DCCF33</gtr:id><gtr:firstName>Li</gtr:firstName><gtr:surname>Wei</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0FF1CBF5-879F-4461-AE1E-EA74A28D69F2"><gtr:id>0FF1CBF5-879F-4461-AE1E-EA74A28D69F2</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Graeme</gtr:otherNames><gtr:surname>Houston</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/22E920E1-0E68-4227-BAB4-BFAA57D96741"><gtr:id>22E920E1-0E68-4227-BAB4-BFAA57D96741</gtr:id><gtr:firstName>Allan</gtr:firstName><gtr:surname>Struthers</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2C7A7F59-1194-4026-8C5E-A2F6C6FA3137"><gtr:id>2C7A7F59-1194-4026-8C5E-A2F6C6FA3137</gtr:id><gtr:firstName>Jacob</gtr:firstName><gtr:surname>George</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0701592"><gtr:id>EF5458E5-8BA8-4DFF-86E0-E574434FE7F2</gtr:id><gtr:title>Xanthine Oxidase inhibitors as a novel way to regress Left Ventricular Hypertrophy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701592</gtr:grantReference><gtr:abstractText>The public are unaware of the huge risk factor of LVH. This study will focus attention on it and hopefully a new way to reduce this huge risk factor.</gtr:abstractText><gtr:technicalSummary>Left ventricular hypertrophy (LVH) is a strong independent risk factor over and above BP. LVH often occurs also in patients with ?normal? BPs but it is unknown how best to further regress LVH in these normotensive patients. Apart from BP, the main other mediator of LVH appears to be oxidative stress. Allopurinol is exceptionally potent at reducing oxidative stress and may therefore be a novel way to regress LVH. In this study, we will screen for and identify 66 individuals with normotensive LVH and chronic stable angina. They will be randomised in a parallel, double blind, randomised fashion to placebo or allopurinol. Cardiac MR will be used both before and 1 year after randomisation to see if allopurinol significantly reduces LV mass more than placebo. We will also see if allopurinol improves endothelial dysfunction in these LVH patients. This study has the potential to identify a novel way to reduce the strong independent risk factor of LVH. Since current therapy cannot eliminate this risk factor, new ways of doing so are urgently required and allopurinol is the most promising option available.</gtr:technicalSummary><gtr:fund><gtr:end>2011-04-06</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-02-07</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>246119</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5AF5BF53-AA5B-406F-99C5-9F2E0219BA57"><gtr:id>5AF5BF53-AA5B-406F-99C5-9F2E0219BA57</gtr:id><gtr:title>High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fde17db083b7a79e82e2fbd0ddec72c8"><gtr:id>fde17db083b7a79e82e2fbd0ddec72c8</gtr:id><gtr:otherNames>Rekhraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701592</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>